1. The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?
    Dylan M. Glubb et al, 2017, Front. Pharmacol. CrossRef
  2. PAMAM dendrimers in drug delivery: loading efficacy and polymer morphology
    P. Chanphai et al, 2017, Can. J. Chem. CrossRef
  3. Nonsteroidal estrogen receptor isoform-selective biphenyls
    Seema Bhatnagar et al, 2018, Chem Biol Drug Des CrossRef
  4. Tamoxifen enhances stemness and promotes metastasis of ERα36<sup>+</sup> breast cancer by upregulating ALDH1A1 in cancer cells.
    Qiang Wang et al, 2018, Cell Res CrossRef
  5. Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study.
    Lizhi Zhang et al, 2016, Mol Cell Endocrinol CrossRef
  6. The Effect of Tamoxifen on Thin Endometrium in Patients Undergoing Frozen–Thawed Embryo Transfer
    Hanni Ke et al, 2018, Reprod Sci CrossRef
  7. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy
    C. A. Fleming et al, 2018, Br J Surg CrossRef
  8. Hormone therapy in menopausal women with fibroids
    Vedhapriya Srinivasan et al, 2018, Menopause CrossRef
  9. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer
    Eylem Kulkoyluoglu et al, 2016, Steroids CrossRef
  10. Review of risk factors of secondary cancers among cancer survivors
    Charlotte Demoor-Goldschmidt et al, 2018, BJR CrossRef
  11. null
    Christina Salazar et al, 2018 CrossRef
  12. Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers
    Thu H Truong et al, 2018 CrossRef
  13. G-Protein Coupled Estrogen Receptor in Breast Cancer.
    Li-Han Hsu et al, 2019, Int J Mol Sci CrossRef
  14. A Short Review on the Delivery of Breast Anticancer Drug Tamoxifen and its Metabolites by Serum Proteins
    Tajmir Riahi HA, 2016, JNMR CrossRef
  15. Estrogen receptor signaling mechanisms.
    Nathalie Fuentes et al, 2019, Adv Protein Chem Struct Biol CrossRef
  16. null
    Robert Clarke, 2019 CrossRef
  17. Characterization of Drug-like Chemical Space for Cytotoxic Marine Metabolites Using Multivariate Methods
    Ramesh Jagannathan, 2019, ACS Omega CrossRef
  18. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen
    Li-jie Wang et al, 2016, Acta Pharmacol Sin CrossRef
  19. 1,2,4-Oxadiazole-5-ones as analogues of tamoxifen: synthesis and biological evaluation
    Maria A. Chiacchio et al, 2019, Org. Biomol. Chem. CrossRef
  20. Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.
    Amanda B Spurdle et al, 2017, Mod Pathol CrossRef
  21. Mice lacking NF-κB1 exhibit marked DNA damage responses and more severe gastric pathology in response to intraperitoneal tamoxifen administration
    Michael D Burkitt et al, 2017, Cell Death Dis CrossRef
  22. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials.
    Rola El Sayed et al, 2019, Front Oncol CrossRef
  23. Tamoxifen use as a malignancy risk factor in postmenopausal women with endometrial polyps
    Daniela Angerame Yela et al, 2019, Menopause CrossRef
  24. Endometrial polyps: when to resect?
    Julia Marques da Rocha de Azevedo et al, 2016, Arch Gynecol Obstet CrossRef
  25. Endocrine resistance in breast cancer--An overview and update.
    Robert Clarke et al, 2015, Mol Cell Endocrinol CrossRef
  26. Aromatase: Contributions to Physiology and Disease in Women and Men
    Jennifer Blakemore et al, 2016, Physiology CrossRef
  27. Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors
    Ivana Šestak et al, 2016, Expert Review of Endocrinology & Metabolism CrossRef
  28. Review on the targeted conjugation of anticancer drugs doxorubicin and tamoxifen with synthetic polymers for drug delivery
    S. Sanyakamdhorn et al, 2017, Journal of Biomolecular Structure and Dynamics CrossRef
  29. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune–Albright syndrome
    Andrea Estrada et al, 2016 CrossRef
  30. null
    Felicity Paterson et al, 2016 CrossRef
  31. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
    Yuan Huang et al, 2017 CrossRef
  32. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility
    Alkistis Skalkidou et al, 2017 CrossRef
  33. Tamoxifen-Dependent Induction ofAGR2Is Associated with Increased Aggressiveness of Endometrial Cancer Cells
    Roman Hrstka et al, 2017, Cancer Investigation CrossRef
  34. Glycinated fullerenes for tamoxifen intracellular delivery with improved anticancer activity and pharmacokinetics
    Charu Misra et al, 2017, Nanomedicine CrossRef
  35. null
    Silvia Dellapasqua, 2017 CrossRef
  36. Hormone therapy in menopausal women with fibroids: is it safe? (Literature review)
    Ya. Z. Zaydieva, 2019, Medicinskij alfavit CrossRef
  37. Alginate based tamoxifen/metal dual core-folate decorated shell: Nanocomposite targeted therapy for breast cancer via ROS-driven NF-κB pathway modulation
    Omar M. Ibrahim et al, 2020, International Journal of Biological Macromolecules CrossRef
  38. Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen
    Cristina Ferraris et al, 2020, Breast Cancer Res Treat CrossRef
  39. Application and biomolecular study of functionalized folic acid-dendrimer nanoparticles in drug delivery
    P. Chanphai et al, 2020, Journal of Biomolecular Structure and Dynamics CrossRef
  40. Drug-Related Carcinogenesis: Risk Factors and Approaches for Its Prevention
    G. A. Belitskiy et al, 2020, Biochemistry Moscow CrossRef
  41. Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer
    Gregory L. Branigan et al, 2020, JAMA Netw Open CrossRef
  42. SWATH-MS Analysis of FFPE Tissues Identifies Stathmin as a Potential Marker of Endometrial Cancer in Patients Exposed to Tamoxifen
    Lucia Janacova et al, 2020, J. Proteome Res. CrossRef
  43. Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells
    Vijay Pandey et al, 2017, Oncotarget CrossRef
  44. Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition
    Robert B. Wilson et al, 2020, IJMS CrossRef
  45. Fasting-mimicking diet and hormone therapy induce breast cancer regression
    Irene Caffa et al, 2020, Nature CrossRef
  46. Minireview: Lymphangioleiomyomatosis (LAM): The “Other” Steroid-Sensitive Cancer
    Hen Prizant et al, 2016 CrossRef
  47. Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination
    Ahmed E. Goda et al, 2020, Toxicology and Applied Pharmacology CrossRef
  48. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug
    Günter Emons et al, 2020, Cancers CrossRef
  49. Protein modification by thiolactone homocysteine chemistry: a multifunctionalized human serum albumin theranostic
    Tatyana V. Popova et al, 2020, RSC Med. Chem. CrossRef
  50. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen
    Atanas Ignatov et al, 2020, Cancers CrossRef
  51. Enhancing endocrine therapy activity via fasting cycles: biological rationale and clinical feasibility
    Irene Caffa et al, 2020, Molecular & Cellular Oncology CrossRef
  52. Adipose-Derived VEGF–mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women
    Subhransu S. Sahoo et al, 2018, Mol Cancer Res CrossRef
  53. null
    Sreedevi Muttathuveliyil Sivadasan et al, 2021 CrossRef
  54. Atypical vessels in hysteroscopy: Usefulness in prediction of malignant diseases in patients treated with tamoxifen
    Emiko Oka et al, 2021, Hysteroscopy of the endometrium with TAM CrossRef
  55. Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors
    Anh S. Lu et al, 2021, Mol. Pharmaceutics CrossRef
  56. Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer
    Ho Tsoi et al, 2021, Cancers CrossRef
  57. Tamoksifen Kullanan Hastaların Jinekolojik Yönden Değerlendirilmesi
    Ümran KÜÇÜKGÖZ GÜLEÇ et al, 2021 CrossRef
  58. Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues
    Ka-Ying Wong et al, 2021, Journal of Ethnopharmacology CrossRef
  59. Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development
    Olga Kondrashova et al, 2021, Cancers CrossRef
  60. Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report
    Omar F. Altal et al, 2021, J Med Case Reports CrossRef
  61. FLTX2: A Novel Tamoxifen Derivative Endowed with Antiestrogenic, Fluorescent, and Photosensitizer Properties
    Mario Díaz et al, 2021, IJMS CrossRef
  62. The Central Roles of Noncoding RNA in Estrogen-Dependent Female Reproductive System Tumors
    Jiajie Tu et al, 2021, International Journal of Endocrinology CrossRef
  63. Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases
    Aditi Sharma et al, 2020, CDT CrossRef
  64. null
    Lorena Incorvaia et al, 2021 CrossRef
  65. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment
    Jian-Jia Liang et al, 2021, European Journal of Medicinal Chemistry CrossRef
  66. Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer
    Nguyen Xuan Thang et al, 2022, Biomedicines CrossRef
  67. Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study
    Danbee Kang et al, 2022, Sci Rep CrossRef
  68. Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)
    Jianyu Lu et al, 2022, Bioorganic & Medicinal Chemistry Letters CrossRef
  69. Early manifestation and progressive multicomponent current of McCune–Albright-Braitsev syndrome in a girl 9 years old: a clinical case and literature review
    Ya. V. Girsh et al, 2021, Probl Endokrinol (Mosk) CrossRef
  70. Educational Case: Endometrial carcinoma types I and II
    Zachary A. Hemann et al, 2022, Academic Pathology CrossRef
  71. Tamoxifen: The Past, Present, and Future of a Previous Orphan Drug
    Ghadier Matariek et al, 2022, EJMED CrossRef
  72. In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
    Gary J. Cheng et al, 2022 CrossRef
  73. Computational Approaches to Identify a Novel Binding Site of BHPI on Estrogen Receptor Alpha
    Monica L. Bean et al, 2022, Steroids CrossRef
  74. Regulation of progesterone receptor expression in endometriosis, endometrial cancer, and breast cancer by estrogen, polymorphisms, transcription factors, epigenetic alterations, and ubiquitin-proteasome system
    Huijie Pu et al, 2022, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
  75. null
    Michelle Frankland et al, 2022 CrossRef
  76. Molecular Biomarker Expression in Window of Opportunity Studies for Oestrogen Receptor Positive Breast Cancer—A Systematic Review of the Literature
    James W. M. Francis et al, 2022, Cancers CrossRef
  77. Discovery of Highly Functionalized 5-hydroxy-2H-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen
    Miguel Guerra-Rodríguez et al, 2022, Cancers CrossRef
  78. DOK7 CpG hypermethylation in blood leukocytes as an epigenetic biomarker for acquired tamoxifen resistant in breast cancer
    Erfan Gowdini et al, 2022, J Hum Genet CrossRef
  79. The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness
    Karla Andrade de Oliveira et al, 2023, Front. Endocrinol. CrossRef
  80. Hormone replacement therapy alone or in combination with tamoxifen in women with thin endometrium undergoing frozen-thawed embryo transfer: A retrospective study
    Qingqing Shi et al, 2023, Front. Endocrinol. CrossRef
  81. Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
    Matin Ghanavati et al, 2023, Cancer Reports CrossRef
  82. null
    Rida Fatima Saeed et al, 2023 CrossRef
  83. STAT3 Signaling Axis and Tamoxifen in Breast Cancer: A Promising Target for Treatment Resistance
    Mohammad Yasin Zamanian et al, 2023, ACAMC CrossRef
  84. Breast cancer therapies reduce risk of Alzheimer’s disease and promote estrogenic pathways and action in brain
    Gregory L. Branigan et al, 2023, iScience CrossRef
  85. TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth
    Yuanqin Zhang et al, 2023, Cancers CrossRef
  86. null
    Vertika Singh et al, 2023 CrossRef
  87. The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors
    Jianbin Guo et al, 2024, Arch Gynecol Obstet CrossRef
  88. The ethanolic extract of Aframomum angustifolium seeds protects against tamoxifen-induced side effects in rats with breast cancer
    Inelle Makamwe et al, 2024, ADV TRADIT MED (ADTM) CrossRef
  89. Rare Mullerian adenosarcoma of the uterine cervix arising on a background of endometriosis: A diagnostic challenge with risk of malignant transformation—A case report and review of the current literature
    Hannah Bruguier et al, 2024, Clinical Case Reports CrossRef
  90. Impact of estradiol in inducing endometrial cancer using RL95-2
    Anuja Pant et al, 2024, Pathology - Research and Practice CrossRef
  91. Comparative sequencing study of mismatch repair and homology‐directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan
    Ying Zheng et al, 2024, Intl Journal of Cancer CrossRef
  92. Anticancer Potential of Ethanolic Extract of Xylopia aethiopica (Dunal) A. Rich (Annonaceae) Dried Fruits on Breast Adenocarcinoma: In Vitro and In Vivo Evidences
    Merline Ymele Nguedia et al, 2024, Environmental Toxicology CrossRef
  93. Spatio‐temporal localization of P21‐activated kinase in endometrial cancer
    Joydeep Roy et al, 2024, Biotech and App Biochem CrossRef
  94. Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer
    Zhendong Qin et al, 2024, Front. Oncol. CrossRef
  95. Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations
    Maha AlDoughaim et al, 2024, Clin Med Insights Oncol CrossRef
  96. Coexistence of Gynecological Pathologies in Women With Cervical and Endometrial Polyps
    Aikaterini Sidera et al, 2025 CrossRef
  97. Potential cervical anticancer activity of tomcat beetle (Paederus fuscipes) compounds against estrogen alpha receptor (3ert): In silico study
    Nadya Latifa et al, 2024, BIO Web Conf. CrossRef